Can scans and blood predict CAR T-Cell success?
NCT ID NCT05422521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these tests could spot early signs of the cancer coming back or severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18FDG PET-CT scans and blood samples
- What this could lead to
- If successful, this could help doctors predict how well CAR T-cell therapy works for lymphoma patients and identify side effects earlier.
- What could go wrong
- This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is exploratory and does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OR RELAPSED NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice
Nice, 06000, France